MingMed Biotechnology is a clinical stage company dedicated to developing First-in-Class pharmaceutical products. It has already made significant breakthroughs in developing novel therapies in the fields of ophthalmology, recombinant BoNT, immune-oncology, gene editing-based immunotherapy and pet medicine. According to a press release on PR Newswire, there are more than 10 products in its R&D pipeline, most of which are First-in-Class medications for unmet medical needs and are at clinical stage. MingMed is committed to develop innovative medicines targeting the true causes of diseases.